Kiora Pharmaceuticals (KPRX) Operating Expenses (2014 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Kiora Pharmaceuticals was $12.83 million, up 17.8% year-over-year; for FY2025, it came in at $12.83 million, up 11.5% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of 13.3% (FY2020 to FY2025).
• In prior years, Kiora Pharmaceuticals' Operating Expenses was $11.51 million in FY2024 (-8.6%), $12.59 million in FY2023 (+2.3%), $12.31 million in FY2022 (-13.5%) and $14.24 million in FY2021 (+106.9%).
• Quarterly Operating Expenses has run from a low of $794,437 in Q3 2025 to a high of $7.31 million in Q4 2025 over five years.
• On a year-over-year basis, Operating Expenses increased in three of the last eight quarters, with growth averaging 8.3%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2021, with growth of 439.2%; the weakest was Q3 2025, with a decline of 77.9%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $2.51 million (Q1 2026), $7.31 million (Q4 2025) and $794,437 (Q3 2025).